Mibrex

Rivaroxaban, the active ingredient in Mibrex, is a Direct factor Xa inhibitor presented as an oral tablet for oral use. It is used to reduce the risk of stroke in atrial fibrillation and to treat or prevent venous thromboembolism in various clinical settings.

GNH USA supplies Mibrex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rivaroxaban is indicated for several thrombo‑embolic conditions and works by targeting the coagulation cascade.

- Non‑valvular atrial fibrillation: Reduces the risk of stroke and systemic embolism. - Deep vein thrombosis and pulmonary embolism: Treats existing clots and prevents recurrence. - Post‑operative orthopedic surgery: Provides prophylaxis against venous thromboembolism after joint replacement or fracture repair.

Rivaroxaban may cause a range of adverse reactions, from mild to severe. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Bruising or minor bleeding at sites of injury. - Nosebleeds. - Headache. - Diarrhea. - Nausea. - Mild anemia.

Serious or Rare Side Effects: - Severe or uncontrolled bleeding. - Intracranial hemorrhage. - Spinal or epidural hematoma. - Hepatic injury. - Allergic reactions such as rash or angioedema. - Thrombocytopenia.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients closely.

- Renal function assessment: Adjust dose or avoid use in severe renal impairment. - Bleeding risk review: Monitor for signs of abnormal bleeding. - Concomitant antiplatelet therapy: Evaluate necessity and adjust regimen. - Hepatic impairment: Use with caution in moderate liver disease. - Active pathological bleeding: Contraindicated during ongoing significant hemorrhage. - Store at below 25°C: Keep in the original packaging, protect from moisture and direct sunlight.

Rivaroxaban interacts with several drug classes that can alter its anticoagulant effect.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, heparin): Increases bleeding risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): Raises plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): Lowers effectiveness. - Antiplatelet agents (e.g., clopidogrel, aspirin): Heightens bleeding potential. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): Augments gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): May modestly increase levels. - Selective serotonin reuptake inhibitors (SSRIs) and SNRIs: Potentially increase bleeding. - Herbal supplements (e.g., ginkgo biloba, garlic): May enhance anticoagulant effect. - Statins metabolized by CYP3A4 (e.g., simvastatin): Observe for any change in bleeding tendency.